Valuation: StemRIM

Market Cap 1.84TCr 11Cr 9.94Cr 9.18Cr 8.45Cr 16Cr 1.09TCr 16Cr 109.82Cr 43Cr 534.88Cr 43Cr 42Cr P/E 2024
-13.6x
P/E 2025 -10.2x
Enterprise Value 1.14TCr 7.03Cr 6.17Cr 5.7Cr 5.24Cr 9.89Cr 678.29Cr 10Cr 68Cr 27Cr 331.88Cr 26Cr 26Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
48.62%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 66 01/10/2022
Chief Executive Officer 58 25/10/2023
Chief Administrative Officer - -
Director TitleAgeSince
Director/Board Member 66 01/02/2007
Director/Board Member 58 01/03/2019
Director/Board Member 54 01/10/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 11Cr
-0.67%+1.15%+23.89%-6.52% 6.88TCr
-0.54%+0.38%+36.12%+192.81% 5.21TCr
-3.65%+34.50%+34.50%+34.50% 4.35TCr
-0.58%-0.23%-52.36%-53.82% 4.12TCr
-2.93%+0.40%+59.97%-27.79% 3.04TCr
-3.77%-12.86%+90.31%-52.47% 2.45TCr
-1.36%-0.91%+70.42%+83.86% 2.34TCr
+3.99%+3.12%+3.87%+200.81% 1.98TCr
+0.26%-1.74%+70.47%+125.19% 1.66TCr
Average -0.89%-1.02%+37.47%+55.18% 3.56TCr
Weighted average by Cap. -1.19%-0.46%+30.59%+46.06%

Financials

2024 2025
Net sales - -
Net income -202.2Cr -1.24Cr -1.09Cr -1.01Cr -92.69L -1.75Cr -119.95Cr -1.78Cr -12Cr -4.72Cr -59Cr -4.67Cr -4.57Cr -192.9Cr -1.19Cr -1.04Cr -96.14L -88.42L -1.67Cr -114.43Cr -1.7Cr -11Cr -4.51Cr -56Cr -4.46Cr -4.36Cr
Net Debt -841Cr -5.17Cr -4.53Cr -4.19Cr -3.86Cr -7.27Cr -498.89Cr -7.39Cr -50Cr -20Cr -244.1Cr -19Cr -19Cr -699.4Cr -4.3Cr -3.77Cr -3.49Cr -3.21Cr -6.05Cr -414.89Cr -6.15Cr -42Cr -16Cr -203Cr -16Cr -16Cr
Logo StemRIM
StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.
Employees
45
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B